



Nektar Therapeutics  
201 Industrial Road  
San Carlos, California 94070

*Sender Contact Information*  
P: (650) 620-5990  
F: (650) 620-5360

January 14, 2009

**VIA FACSIMILE AND U.S. MAIL**

Securities and Exchange Commission  
Division of Corporate Finance  
Washington, D.C. 20549  
Attention: Nandini Acharya, Esq.

**Re: Nektar Therapeutics. -- Form 10-K for the Year Ended December 31, 2007 (File No. 000-24006)**

Dear Ms. Acharya:

This request is in relation to the letter dated December 10, 2008 (the "**Comment Letter**"), including comments from the staff of the Securities and Exchange Commission to the Form 10-K for the year ended December 31, 2007 (File No. 000-24006) filed by Nektar Therapeutics, a Delaware corporation, on February 29, 2008.

We respectfully request an extension to January 23, 2009 to provide a response to the Comment Letter.

Please do not hesitate to call the undersigned at (650) 620-5990 or Jennifer A. DePalma, Esq. of O'Melveny & Myers LLP, legal counsel to Nektar Therapeutics, at (650) 473-2670, regarding this matter.

Sincerely,

/s/ Gil M. Labrucherie

**GIL M. LABRUCHERIE**  
Senior Vice President, General Counsel &  
Secretary of Nektar Therapeutics

cc: Howard W. Robin, President and Chief Executive Officer of Nektar Therapeutics  
Sam Zucker, Esq., O'Melveny & Myers LLP  
Jennifer A. DePalma, Esq., O'Melveny & Myers LLP